MARKET

VIR

VIR

VIR BIOTECHNOLOG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.18
+0.87
+2.69%
Opening 09:33 01/27 EST
OPEN
32.28
PREV CLOSE
32.31
HIGH
33.18
LOW
32.28
VOLUME
25.60K
TURNOVER
--
52 WEEK HIGH
141.01
52 WEEK LOW
29.48
MARKET CAP
4.34B
P/E (TTM)
-39.1921
1D
5D
1M
3M
1Y
5Y
Glaxo's (GSK) New Drugs Drive Sales Amid Rising Competition
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.
Zacks · 23h ago
U.S. FDA to restrict use of Regeneron, Lilly COVID antibody drugs - WaPo
reuters.com · 2d ago
Northside Capital Management, LLC Buys Snowflake Inc, Datadog Inc, Procore Technologies Inc, ...
Hood River, OR, based Investment company Northside Capital Management, LLC (Current Portfolio) buys Snowflake Inc, Datadog Inc, Procore Technologies Inc, Planet Labs PBC, Trane Technologies PLC, sells Vir Biotechnology Inc, Roblox Corp, Oracle Corp, Abbott...
GuruFocus.com · 2d ago
FDA to restrict COVID-19 antibody therapies from Regeneron and Eli Lilly - WaPo
The FDA is planning to restrict the COVID-19 monoclonal antibody therapies developed by Regeneron (REGN -3.0%) and Eli Lilly (LLY -3.8%) citing their lack of efficacy against the Omicron variant, The
Seekingalpha · 2d ago
UK Stocks-Factors to watch on Jan 24
reuters.com · 3d ago
GSK, Vir ramping up U.S. output of COVID antibody drug
reuters.com · 5d ago
NIH says Pfizer's Paxloid should be first treatment option for certain COVID-19 patients
The National Institutes of Health on Wednesday updated its COVID-19 treatment guidelines for patients with mild to moderate forms of COVID-19 who are at high risk for disease progression. The new guidelines now include the recently authorized antivirals de...
marketwatch.com · 01/20 13:42
bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down
The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.
Zacks · 01/19 16:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIR. Analyze the recent business situations of VIR BIOTECHNOLOG through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

12.50%Strong Buy
50.00%Buy
25.00%Hold
0.00%Under-perform
12.50%Sell
Analyst Price Target
The average VIR stock price target is 91.43 with a high estimate of 300.00 and a low estimate of 36.00.
High300.00
Average91.43
Low36.00
Current 32.31
EPS
Actual
Estimate
-0.610.090.801.51
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 202
Institutional Holdings: 74.75M
% Owned: 57.11%
Shares Outstanding: 130.88M
TypeInstitutionsShares
Increased
63
3.30M
New
36
1.14M
Decreased
45
6.19M
Sold Out
25
832.49K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.73%
Pharmaceuticals & Medical Research
-0.45%
Key Executives
Non-Executive Chairman/Independent Director
Vicki Sato
President/Chief Executive Officer/Director
George Scangos
Chief Financial Officer/Secretary
Howard Horn
Executive Vice President/Chief Scientific Officer
Herbert Virgin
Chief Technology Officer
Ann Hanly
Chief Administrative Officer
Steven Rice
Other
Phil Pang
Independent Director
Jeffrey Hatfield
Independent Director
Robert More
Independent Director
Janet Napolitano
Independent Director
Robert Nelsen
Independent Director
Dipchand Nishar
Independent Director
Robert Perez
Independent Director
Saira Ramasastry
Independent Director
Phillip Sharp
Independent Director
Elliott Sigal
No Data
About VIR
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on treating and preventing serious infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. Its development pipeline consists of product candidates targeting the coronavirus disease 2019 (COVID-19), hepatitis B virus (HBV), influenza A virus and human immunodeficiency virus (HIV). Its product candidates include VIR-7831 and VIR-7832, VIR-2218, VIR-3434, VIR-2482 and VIR-111. The Company is developing VIR-7831 and VIR-7832 for the treatment of COVID-19 infection, which are severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing monoclonal antibody (mAbs). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb.VIR-1111 is a subcutaneously administered HIV T cell vaccine.

Webull offers kinds of Vir Biotechnology Inc stock information, including NASDAQ:VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIR stock methods without spending real money on the virtual paper trading platform.